Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals, Inc. (symbol: VRPX) is a pioneering biopharmaceutical company dedicated to developing advanced drug delivery systems aimed at improving patient compliance and achieving therapeutic efficacy. Specializing in non-opioid pain management, Virpax is committed to enhancing patients' quality of life through innovative pharmaceutical products.
As a preclinical stage company, Virpax focuses on creating branded pharmaceutical products for pain management. Their impressive product portfolio includes:
- Topical Metered-Dose Spray: A novel approach for localized pain relief.
- Liposomal in Hydrogel Encapsulation: A cutting-edge technology designed to enhance drug delivery and efficacy.
- Enkephalin Intranasal Spray: An innovative treatment method aimed at providing rapid pain relief.
Virpax Pharmaceuticals collaborates with a network of U.S. and global partners to advance the development of its proprietary drug platforms. Their goal is to become a global leader in non-opioid pain management, creating value for investors and partners alike.
Recent achievements and current projects highlight Virpax’s commitment to innovation. These include advancing their drug candidates through preclinical stages, securing strategic partnerships, and working towards regulatory approvals.
Financially, Virpax Pharmaceuticals is focused on sustainable growth, leveraging cutting-edge technology to develop products that meet the unmet needs of pain management patients. The company’s strategic initiatives are designed to enhance shareholder value while pushing the boundaries of pharmaceutical advancements.
Stay tuned for the latest updates and exciting developments from Virpax Pharmaceuticals as they continue to make strides in the biopharmaceutical industry.
Virpax Pharmaceuticals announced the pricing of a public offering totaling $2.25 million. This offering includes 1,666,667 shares of common stock and Series A-1 and A-2 warrants. The shares and warrants are priced at $1.35 each, with Series A-1 warrants expiring in five years and Series A-2 in eighteen months. The offering is expected to close around May 17, 2024, subject to customary conditions. The securities are being offered under a registration statement filed with the SEC.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced its Q1 2024 results and recent developments. The company reported an increase in general and administrative expenses to $1.7M and R&D expenses to $1.6M, leading to an operating loss of $3.2M. Cash reserves stood at $1.9M as of March 31, 2024. Key highlights include the positive results of the Probudur™ Maximum Tolerated Dose Study, ongoing development of Envelta™ and NobrXiol™, and a settlement agreement with Sorrento Therapeutics and Scilex Pharmaceuticals. The company is also seeking additional grants and licensing opportunities. CEO Gerald W. Bruce expressed optimism about the future despite the financial challenges.
Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine. The formulation demonstrated the potential to offer rapid onset and prolonged action, marking significant progress towards completing preclinical studies and filing for an Investigational New Drug Application (IND) by the end of the year.
FAQ
What is the current stock price of Virpax Pharmaceuticals (VRPX)?
What is the market cap of Virpax Pharmaceuticals (VRPX)?
What does Virpax Pharmaceuticals, Inc. specialize in?
What are some of Virpax Pharmaceuticals' key products?
Is Virpax Pharmaceuticals a preclinical stage company?
What is Virpax's goal in the pharmaceutical industry?
How does Virpax enhance the efficacy of its products?
Who does Virpax collaborate with for its developments?
What type of spray is included in Virpax's product portfolio?
How is Virpax Pharmaceuticals enhancing shareholder value?
What technology does Virpax use for drug encapsulation?
Where can I find the latest news about Virpax Pharmaceuticals?
